NGAL immunohistochemical expression in brain primary and metastatic tumors

Clinical Neuropathology

Volumn 29, Issue 5, 2010, Pages 317-322

  Barresi, V ^a   Tuccari, G ^a   Barresi, G ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Brain tumor; Glioblastoma; Immunohistochemistry; Meningioma; Metastasis; NGAL

Indexed keywords

ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; FEMALE; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; SECONDARY; YOUNG ADULT;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; FEMALE; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; YOUNG ADULT;

EID: 77956666899     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp29317     Document Type: Article

References (30)

1. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maas N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 2008; 108: 389-397.
2. Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin (NGAL) in macroproteinuric patients with worsening renal function. Kidney Blood Press Res. 2008; 31: 274-279.
3. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008; 52: 595-605.
4. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2009; 17: epub ahead of print.
5. Bratt T. Lipocalins and cancer. Biochim Biophys acta. 2000; 1482: 318-326.
6. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004; 22: 499-506.
7. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997; 45: 17-23.
8. Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. 2007; 5: 463-470.
9. Devireddy LR, Gazin C, Zhu X, Green MR. Acell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 2005; 23: 1293-1305.
10. Fernandez CA, Yan L, Louis G, Yang J, Louis G, Yang J, Kutok JL, Moses M.: The matrix metalloproteinase-9/neutrophil gelatinase associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005; 11: 5390-5395.
11. Friedl A, Stoesz SP, Buckley, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999; 31: 433-441.
12. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002; 10: 1033-1043.
13. Goetz DH, Willie ST, Arme RS, Bratt T, Borregaard N, Strong RK. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000; 39: 1935-1941.
14. Gwira JA, Wei F, Ishibe S. Expression of neutrophil associated-gelatinase lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem. 2005; 280: 7875-7882.
15. Hannai J, Mammoto T, Seth P et al. Lipocalin2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem. 2005; 280: 3641-3647.
16. Iannetti A, Pacifico F, Acquaviva R , Lavorgna A, Crescenzi E, Vascotto C, Tell G, Salzano AM, Scaloni A, Vuttariello E, Chiappetta G, Formisano S, Leonardi A. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A. 2008; 105: 14058-14063.
17. Le NTV, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys acta. 2002; 1603: 3146.
18. Lee S, Jilani SM, Nikolova GV, Carpizo D and Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005; 169: 681-691.
19. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, Quinn MA, Rice GE. Neutrophil gelatinase-associated lipocalin (NGAL) an early screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer. 2007; 120: 2426-2434.
20. Mori K, Yang J, Barasch J. Ureteric bud controls multiple steps in the conversion of mesenchyme to epithelia. Semin Cell Dev Biol. 2003; 14: 209-216.
21. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996; 38: 414-420.
22. Perry A, Louis DN, Scheithauer BW et al. Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO Classification of Tumors of the Central Nervous System. Lyon: IARCC press, 2007. 164-172.
23. Smith ER, Manfredi M, Scott RM, Black PM, Moses MA. Case of a recurrent craniopharyngioma used to illustrate the potential utility of urinary matrix metalloproteinases as non-invasive biomarkers. Neurosurgery. 2007; 60: 1148-1149.
24. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008; 14: 2378-2386.
25. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancer. Breast Cancer Res Treat. 1998; 79: 565-572.
26. Stoesz SP, Gould MN. Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. Oncogene. 1995; 11: 2233-2241.
27. Toyokuni S. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci. 2009; 100: 9-16.
28. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001; 276: 37258-37265.
29. Yang J, Goetz D, Li JY, Wang W, Mori K and Setlik D. An iron delivery pathway mediated by a lipocalin. Mol Cell. 2002; 10: 1045-1056.
30. Zhang XF, Zhang Y, Zhang XH, Zhou SM, Yang GG, Wang OC, Guo GL, Yang GY, Hu XQ. Clinical significance of Neutrophil gelatinase-associated lipocalin (NGAL) expression in primary rectal cancer. BMC Cancer. 2009; 9: 134.